Dr. Wong has published extensively in the field of interventional cardiology with special focus on new device angioplasty, saphenous vein graft intervention, cardiogenic shock, and drug eluting stent. His current clinical research interests include novel drug eluting stent designs, access site and PFO closure devices, percutaneous valve repair, and application of stem cell technology in the treatment of myocardial ischemia. In the past five years, Dr. Wong and his colleagues had participated in multiple US pivotal trials that led to the FDA approval of both drug eluting stents for the treatment of symptomatic obstructive coronary artery disease. Dr. Wong has recently served as the national principal investigation in the ECLIPSE trial which evaluated the safety and efficacy of an extra-vascular bio-degradable access site closure device in patients undergoing coronary or peripheral diagnostic/interventional procedures compare to the standard treatment of manual compression. Other exciting areas of ongoing research include percutaneous treatment valvular disease states including mitral regurgitation and aortic stenosis, assessment of novel pharmacologic agents to enhance safety of angioplasty procedures. His clinical research activities have been published in Journal of American College of Cardiology, American Journal of Cardiology, American heart Journal and he has presented his findings at numerous national and international meetings including American Heart Association, American College of Cardiology, Transcatheter Therapeutics, Summer in Seattle, Taiwan Society of Cardiology and Asia Pacific Cardiology Congress. He is recruited to serve as member of the Scientific Advisory Board of multiple major US medical device companies.